Major Histocompatibility Complex Allopeptides in the Rat MOHAMED H

Total Page:16

File Type:pdf, Size:1020Kb

Major Histocompatibility Complex Allopeptides in the Rat MOHAMED H Proc. Natd. Acad. Sci. USA Vol. 89, pp. 7762-7766, August 1992 Immunology Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat MOHAMED H. SAYEGH*, SAMIA J. KHOURYt, WAYNE W. HANCOCKO, HOWARD L. WEINERt, AND CHARLES B. CARPENTER* *Laboratory of Immunogenetics and Transplantation, Renal Division, and tCenter for Neurologic Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; and tDepartment of Immunology and Pathology, Monash Medical School, Prahran, Victoria 3181, Australia Communicated by D. Bernard Amos, May 15, 1992 (receivedfor review, January 24, 1992) ABSTRACT We studied the immunogenicit and tolero- immunogenicity and tolerogenicity of orally administered genicity of class II major histocompatibility complex (MHC) synthetic MHC allopeptides in the rat. allopeptides in the rat. Inbred LEW (RT1') rats, used as responders, were immunized in the foot pad with a mixture of MATERIALS AND METHODS eight synthetic class H MHC allopeptides emulsified in com- plete Freund's adjuvant. These sequences represent the full- Animals. LEW, WF, and BN rats, 8-10 weeks old, were length second domain of RTl.Bu and RT1.Du (WF) (3 chains. obtained from Harlan-Sprague-Dawley or were bred in our In vitro, responder lymphocytes harvested from popliteal and own animal facility. inguinal lymph nodes of immunized animals exhibited signff- Allopeptides. We selected the RT1.B (3 and RT1.D (3 icant proliferation to the MHC allopeptide mixture. In addi- domains of RTlU (WF) and synthesized four overlapping tion, these responder lymphocytes had significantly increased peptides of 20-25 amino acids (residues 1-25, 20-44, 39-64, proliferation to allogeneic WF (RTl") stimulator cells, when and 68-92 for RT1.B and residues 1-25, 20-44, 39-64, and 60-84 for RT1.D) for each locus, by using published se- compared to naive controls in the standard one-way mixed quences of the class II ( chain (8). Fig. 1 shows these lymphocyte response. In vivo, peptide-immunized LEW ani- polymorphic sequences aligned with those of the (B chains of mals were challenged in the ear 2 weeks after immunization RT11 (LEW). Peptides that were used for in vitro proliferation with the allopeptide mixture, the individual allopeptide se- assays were purified by HPLC yielding >95% purity as quences, or allogeneic WF splenocytes. When compared to determined by amino acid analysis. controls, these animals had significant delayed-type hypersen- Proliferation Assays. Responder LEW rats were immu- sitivity responses to the allopeptide mixture, to the (-pleated nized subcutaneously in the foot pad with 100 ,ug of the sheet allopeptide sequences, and to allogeneic WF splenocytes mixture of the four RT1.Bu and four RT1.Du peptides (each but not to the a-helix allopeptide sequences, to syngeneic LEW at 12.5 ug) in complete Freund's adjuvant (CFA). Popliteal splenocytes, or to third party allogeneic BN splenocytes. Oral and inguinal lymph nodes were harvested 1 week after administration of the allopeptide mixture to LEW responder immunization and mashed through 60-gauge sterile stainless rats daily for 5 days before immunization effected significant steel sieves. The recovered cells were then washed twice and reduction ofdelayed-type hypersensitivity responses both to the resuspended into RPMI 1640 medium (Microbiological As- allopeptide mixture and to allogeneic splenocytes. This reduc- sociates), containing 10%o (vol/vol) fetal calfserum, penicillin tion was antigen-specific, since there was no reduction of (100 units/ml), streptomycin (100 ,gg/ml), 20 LM 2-mercap- delayed-type hypersensitivity responses to mycobacterium tu- toethanol, and 5 mM Hepes. T and B cells were separated by berculosis. These data demonstrate that lymphocytes from nylon adherence as described (9). Responder unseparated animals immunized with polymorphic class II MHC allopep- LEW lymphocytes (3 x 105 cells) were cultured in 96-well tides can recognize and proliferate to the same amino acid flat-bottom plates (Costar) with 10-50 ,g of the mixture of sequences on allogeneic cell surface MHC molecules. In addi- RT1.Bu, RT1.Du, or both, sets of allopeptides. In other tion, oral administration of these peptides down-regulates the experiments, 1 x 105 nylon-wool-adherant cells, used as systemic cell-mediated immune response in a specific fashion. antigen-presenting cells, were preincubated with 10-50 Pg of Synthetic MHC allopeptides should allow the study of alloim- the RT1.Bu, RT1.Du, or both, sets of allopeptides for 30 min munity in vivo, including induction of immune tolerance. at 370C. The cells were then washed twice to remove excess peptides before adding 2 x 105 nylon-wool-nonadherent Recent work with synthetic peptides representing portions of responder T cells. Negative control wells were set up with the polymorphic regions of mouse and human class I and II culture medium only. LEW x WF one-way mixed lympho- major histocompatibility complex (MHC) molecules indi- cyte responses (MLRs) were set up by using equal numbers cates that they can be bound to MHC molecules and elicit a of responder LEW and allogeneic WF stimulator lympho- T-cell response in vitro (1-5). There is no information on the cytes (prepared as described for LEW lymphocytes and induction irradiated with 3000 rads; 1 rad = 0.01 Gy) per well. The of immunity or tolerance by administration of plates were incubated at 370C with 5% C02/95% airfor 4 days synthetic MHC peptides in vivo. The oral route of adminis- before they were pulse-labeled for 6 h with [3H]thymidine (1 tration of antigens has been shown to induce immune hypo- ACi per well; 1 Ci = 37 GBq; NEN/DuPont) and harvested responsiveness (6). In alloimmunity, we have recently re- with a PHD cell harvester (Cambridge Technology, Cam- ported (7) that oral administration of allogeneic splenocytes bridge, MA). Proliferation was assayed by [3H]thymidine to inbred rats down-regulates the systemic cell-mediated incorporation measured by a Beckman liquid scintillation immune response in vitro and in vivo. We now report on the Abbreviations: MHC, major histocompatibility complex; MLR, The publication costs ofthis article were defrayed in part by page charge mixed lymphocyte response; DTH, delayed-type hypersensitivity; payment. This article must therefore be hereby marked "advertisement" CFA, complete Freund's adjuvant; EAE, experimental autoimmune in accordance with 18 U.S.C. §1734 solely to indicate this fact. encephalomyelitis. 7762 Downloaded by guest on September 26, 2021 Immunology: Sayegh et al. Proc. NatL. Acad. Sci. USA 89 (1992) 7763 10 20 30 40 50 A RT1 .Bpu QRLRRDFLVQFKPYCYFTNGTQRIRNVIRYIYNREEYLRYDSDVGEYRAV RT1.D ....................... ----------Q-0-------------Q --J-. 60 70 80 90 TELGRPSAEYFNKQ*Y*LERTRAELDTVCRHNYEKTEVPTSL RTL.B 10 20 30 40 50 Pep. Mix. RT1.D u RDPTPRFLGYLKPECHFYNGTNRVRLLARLIYNREEYARFDSDVGEYRAV 0 100,000 300,000 cpm RT1. ..............................Y-------T--------F--- Medium 60 70 80 90 TELGRPSAEYRNKQKEPMERRRATVDTYCRHNYEIFDRFL 0 20,000 40,000 60,000 80,000 cpm ----------Y-----Y--QI------A-K-D-....... B FIG. 1. Amino acid sequences ofthe synthetic MHC RT1.BU and RT1.D RT1.DU peptides aligned with those of RT11. Dots denote unknown sequences, dashes denote identical sequences, and asterisks denote absent sequences. RT1.B counter. Experiments were set up in quadruplicate, and results are expressed as cpm (mean SEM) or relative Pep. Mix. d1 response = (experimental cpm - background cpm)/(control cpm - background cpm). Delayed-Type Hypersensitivity (DTH) Response. LEW rats, Medium used as responders, were immunized subcutaneously in the 0I foot pad with 100 pg ofthe mixture offour RT1.BU (50 jug) and 0 20,000 40,000 60,000 80,000 100,000 four RT1.Du (50 pg) peptides (12.5 jug of each peptide) in cpm CFA. These animals were challenged subcutaneously 2 weeks later in one ear with 10 jug of the peptide mixture and FIG. 2. (A) Direct proliferation of lymphocytes harvested from in the other ear with 1 x 107 freshly prepared and irradiated LEW rats, naive (shaded bars) and immunized with the entire (3000 rads) splenocytes from WF (RTlu), syngeneic LEW allopeptide mixture (solid bars), that were incubated with the entire (RT11), or a third party, BN (RT1n). The DTH responses were peptide mixture (bars Pep.Mix) or RT1.B or RT1.D allopeptides. measured with micrometer caliper Field Tool Bars represent cpm (mean ± SEM) of a representative experiment (Mitutoyo, performed in quadruplicate (five experiments). (Inset) Concomitant Supply, Chicago) by a blinded observer as the change in ear LEW x WF MLR for the experiment shown. The calculated relative thickness before and 2 days after the challenge (inches x response for the MLR was 2.65 + 0.2 (n = 6). (B) Proliferation of 10-2; 1 inch = 2.54 cm). Experiments were performed using nylon-wool-non-adherant mononuclear cells harvested from immu- five animals in each study groups. P values were calculated nized (with the entire allopeptide mixture) LEW animals to the entire using the Student t test. peptide mixture (Pep.Mix) or RT1.B or RT1.D allopeptides pre- sented by syngeneic nylon-wool-adherant cells. Bars represent cpm (mean + SEM) of a representative experiment performed in qua- RESULTS druplicate (four experiments). Immunogenicity of Class II MHC Allopeptides Assessed in Vitro. To test the immunogenicity ofthe synthetic RT1.B and from animals immunized with these allopeptides proliferate RT1.D allopeptides, lymphocytes harvested from responder more vigorously to allogeneic cell surface MHC molecules. LEW animals immunized with the mixture of eight allopep- Immunogenicity of Class II MHC Allopeptides Assessed by tides 1 week earlier were compared to naive controls for their DTH in Vivo. LEW animals that were immunized with the ability to proliferate to the allopeptides in a standard 96-h entire allopeptide mixture and CFA had significant DTH proliferation assay. As shown in Fig. 2A, whereas naive responses both to the allopeptides and to freshly prepared lymphocytes had only minimal proliferation, immunized an- allogeneic WF splenocytes (Fig.
Recommended publications
  • Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins
    European Medicines Agency London, 13 December 2007 Doc. Ref. EMEA/CHMP/BMWP/14327/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS DRAFT AGREED BY BMWP July 2006 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) July 2007 AGREED BY BMWP October 2007 ADOPTION BY CHMP December 2007 DATE FOR COMING INTO EFFECT April 2008 KEYWORDS Immunogenicity, unwanted immune response, biotechnology derived proteins, immunogenicity risk factors, assays, clinical efficacy and safety, risk management 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS TABLE OF CONTENTS EXECUTIVE SUMMARY................................................................................................................... 3 1. INTRODUCTION......................................................................................................................... 3 2. SCOPE............................................................................................................................................ 4 3. LEGAL BASIS .............................................................................................................................
    [Show full text]
  • Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective
    Risk Assessment and Mitigation Strategies for Immune Responses to Therapeutic Proteins: the FDA Perspective Amy S. Rosenberg, M.D. Supervisory Medical Officer, Office of Biotechnology Products CDER, FDA Risk is a Specific Knowledge Set Encompassing Both Consequences and Probabilities (modified from Stirling and Gee 2002) Knowledge about Consequences Knowledge about likelihoods Consequences Consequences well-defined poorly-defined Some basis Ambiguity Risk (I) for (III) probabilities Incertitude No basis for Uncertainty Ignorance probabilities (II) (IV) “Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products” U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) August 2014 Clinical/Medical 3 Immunogenicity Risk Assessment: Consequences for Safety • Fatality/Severe Morbidity – Anaphylaxis: clinical definition, does not imply mechanism • Proteins of non-human origin, eg, aprotinin, asparaginase • Replacement human proteins in knock out phenotype: eg, Factor IX in hemophilia B – Cross reactive neutralization of endogenous factor or receptor homolog with unique function resulting in deficiency syndrome or cytokine release syndrome – Immune complex disease and delayed hypersensitivity • Serum sickness; nephropathy • Most often seen when high doses of therapeutic proteins are administered in setting of a sustained high titered antibody response Immunogenicity Risk Assessment Consequences for Efficacy
    [Show full text]
  • Measuring the Immunogenicity of Allogeneic Adult Mesenchymal Stem Cells Alix K
    Berglund et al. Stem Cell Research & Therapy (2017) 8:288 DOI 10.1186/s13287-017-0742-8 REVIEW Open Access Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells Alix K. Berglund1*, Lisa A. Fortier2, Douglas F. Antczak3 and Lauren V. Schnabel1* Abstract Background: Autologous and allogeneic adult mesenchymal stem/stromal cells (MSCs) are increasingly being investigated for treating a wide range of clinical diseases. Allogeneic MSCs are especially attractive due to their potential to provide immediate care at the time of tissue injury or disease diagnosis. The prevailing dogma has been that allogeneic MSCs are immune privileged, but there have been very few studies that control for matched or mismatched major histocompatibility complex (MHC) molecule expression and that examine immunogenicity in vivo. Studies that control for MHC expression have reported both cell-mediated and humoral immune responses to MHC-mismatched MSCs. The clinical implications of immune responses to MHC-mismatched MSCs are still unknown. Pre-clinical and clinical studies that document the MHC haplotype of donors and recipients and measure immune responses following MSC treatment are necessary to answer this critical question. Conclusions: This review details what is currently known about the immunogenicity of allogeneic MSCs and suggests contemporary assays that could be utilized in future studies to appropriately identify and measure immune responses to MHC-mismatched MSCs. Keywords: Mesenchymal stem cell, Allogeneic, Immunogenicity, Major histocompatibility complex, Mixed leukocyte reaction, Cytotoxicity, ELISPOT, Microcytotoxicity Background in vivo [9], questioning the relevance of differentiation Mesenchymal stem cells (MSCs) are currently defined as to the therapeutic properties of MSCs when injected in a plastic-adherent cells with a fibroblast-like morphology naive state.
    [Show full text]
  • Size, Affinity, and Immunogenicity Peptide-Binding Repertoires Of
    HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity This information is current as Sinu Paul, Daniela Weiskopf, Michael A. Angelo, John of September 29, 2021. Sidney, Bjoern Peters and Alessandro Sette J Immunol 2013; 191:5831-5839; Prepublished online 4 November 2013; doi: 10.4049/jimmunol.1302101 http://www.jimmunol.org/content/191/12/5831 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/11/05/jimmunol.130210 Material 1.DC1 http://www.jimmunol.org/ References This article cites 51 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/191/12/5831.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and Immunogenicity Sinu Paul,1 Daniela Weiskopf,1 Michael A.
    [Show full text]
  • Immunogenicity Assessment of Therapeutic Proteins
    European Medicines Agency London, 24 January 2007 Doc. Ref. EMEA/CHMP/BMWP/14327/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS DRAFT AGREED BY BMWP July 2006 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION 24 January 2007 END OF CONSULTATION (DEADLINE FOR COMMENTS) 31 July 2007 Comments should be provided electronically in word format using this template to: [email protected] KEYWORDS Immunogenicity, biotechnology derived proteins, antigenicity risk factors, assays, clinical efficacy 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged GUIDELINE ON IMMUNOGENICITY ASSESSMENT OF BIOTECHNOLOGY-DERIVED THERAPEUTIC PROTEINS TABLE OF CONTENTS EXECUTIVE SUMMARY................................................................................................................... 3 1. INTRODUCTION......................................................................................................................... 3 2. SCOPE............................................................................................................................................ 3 3. LEGAL BASIS .............................................................................................................................
    [Show full text]
  • Immune Escape Mechanisms As a Guide for Cancer Immunotherapy Gregory L
    Published OnlineFirst December 12, 2014; DOI: 10.1158/1078-0432.CCR-14-1860 Perspectives Clinical Cancer Research Immune Escape Mechanisms as a Guide for Cancer Immunotherapy Gregory L. Beatty and Whitney L. Gladney Abstract Immunotherapy has demonstrated impressive outcomes for exploited by cancer and present strategies for applying this some patients with cancer. However, selecting patients who are knowledge to improving the efficacy of cancer immunotherapy. most likely to respond to immunotherapy remains a clinical Clin Cancer Res; 21(4); 1–6. Ó2014 AACR. challenge. Here, we discuss immune escape mechanisms Introduction fore, promote tumor outgrowth. In this process termed "cancer immunoediting," cancer clones evolve to avoid immune-medi- The immune system is a critical regulator of tumor biology with ated elimination by leukocytes that have antitumor properties the capacity to support or inhibit tumor development, growth, (6). However, some tumors may also escape elimination by invasion, and metastasis. Strategies designed to harness the recruiting immunosuppressive leukocytes, which orchestrate a immune system are the focus of several recent promising thera- microenvironment that spoils the productivity of an antitumor peutic approaches for patients with cancer. For example, adoptive immune response (7). Thus, although the immune system can be T-cell therapy has produced impressive remissions in patients harnessed, in some cases, for its antitumor potential, clinically with advanced malignancies (1). In addition, therapeutic mono- relevant tumors appear to be marked by an immune system that clonal antibodies designed to disrupt inhibitory signals received actively selects for poorly immunogenic tumor clones and/or by T cells through the cytotoxic T-lymphocyte–associated antigen establishes a microenvironment that suppresses productive anti- 4 (CTLA-4; also known as CD152) and programmed cell death-1 tumor immunity (Fig.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • The Evaluation of Immunogenicity of Therapeutic Antibody Drug Aggregates Using 2D and 3D in Vitro Models
    Dissertation zur Erlangung des Doktorgrades der Fakultät Chemie und Pharmazie der Ludwig-Maximilians-Universität München The evaluation of immunogenicity of therapeutic antibody drug aggregates using 2D and 3D in vitro models Teresa Franziska Kraus aus Weingarten 2019 Erklärung Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Frau PD Dr. habil. Julia Engert betreut. Eidesstattliche Versicherung Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet. München, den 01.05.2019 ____________________________ Teresa Kraus Dissertation eingereicht am: 16.05.2019 1. Gutachter: PD Dr. habil. Julia Engert 2. Gutachter: Prof. Dr. Gerhard Winter Mündliche Prüfung am: 02.07.2019 Für Opa SALUS AEGROTI SUPREMA LEX Hippokrates Acknowledgements This thesis was prepared between March 2015 and December 2018 at the Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics at the Ludwig-Maximilians-Universität München under the supervision of PD Dr. habil. Julia Engert. First and foremost, I would like to express my deepest gratitude to PD Dr. habil. Julia Engert for her excellent supervision and scientific guidance during my PhD time. I’m deeply thankful for her support and help in all research issues, the lively scientific discussions and for always having an open ear. In addition, I highly appreciated her help in preparing publications. I’m deeply grateful to Prof. Dr. Gerhard Winter for giving me the chance to work on an innovative and challenging project. I highly appreciated his outstanding scientific advice and support on a professional but also personal level. Besides the professional aims, he also attached importance to a good team spirit and always supported group activities which created an excellent working atmosphere.
    [Show full text]
  • Antigenicity and Immunogenicity Analysis of the E. Coli Expressed FMDV Structural Proteins; VP1, VP0, VP3 of the South African Territories Type 2 Virus
    viruses Article Antigenicity and Immunogenicity Analysis of the E. coli Expressed FMDV Structural Proteins; VP1, VP0, VP3 of the South African Territories Type 2 Virus Guoxiu Li 1,†, Ashenafi Kiros Wubshet 1,2,*,† , Yaozhong Ding 1, Qian Li 1, Junfei Dai 1, Yang Wang 1, Qian Hou 1, Jiao Chen 1, Bing Ma 1, Anna Szczotka-Bochniarz 3 , Susan Szathmary 4, Yongguang Zhang 1 and Jie Zhang 1,* 1 State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China; [email protected] (G.L.); [email protected] (Y.D.); [email protected] (Q.L.); [email protected] (J.D.); [email protected] (Y.W.); [email protected] (Q.H.); [email protected] (J.C.); [email protected] (B.M.); [email protected] (Y.Z.) 2 Department of Basic and Diagnostic Sciences, College of Veterinary Science, Mekelle University, Tigray 280, Ethiopia 3 Department of Swine Diseases, National Veterinary Research Institute, 57 Partyzantow, 24-100 Puławy, Poland; [email protected] 4 RT-Europe Research Center, H-9200 Mosonmagyarovar, Hungary; [email protected] * Correspondence: nafi[email protected] (A.K.W.); [email protected] (J.Z.); Tel.: +86-13679496049 (J.Z.) † These authors contributed equally to this work. Citation: Li, G.; Wubshet, A.K.; Ding, Abstract: An alternative vaccine design approach and diagnostic kits are highly required against Y.; Li, Q.; Dai, J.; Wang, Y.; Hou, Q.; the anticipated pandemicity caused by the South African Territories type 2 (SAT2) Foot and Mouth Chen, J.; Ma, B.; Szczotka-Bochniarz, Disease Virus (FMDV).
    [Show full text]
  • Induction of Immunogenicity of Monoclonal Antibodies by Conjugation with Drugs David A
    (CANCER RESEARCH 51, 5774-5776, October 15, 1991] Advances in Brief Induction of Immunogenicity of Monoclonal Antibodies by Conjugation with Drugs David A. Johnson,1 Russell L. Barton, Daniel V. Fix, William L. Scott, and Magda C. Gutowski Lilly Research Laboratories, Indianapolis, Indiana 46285 Abstract Materials and Methods Human anti-mouse antibody has been a nearly consistent result of Antibody and Conjugates human clinical trials utilizing murine antibodies. It is generally antici pated that the problem of human anti-mouse antibody will be reduced as A murine monoclonal antibody directed against EGFr (9), 225 IgGl, genetically engineered, more human ("humanized") antibodies become was grown as ascites and purified using traditional protein A Sepharose available. It is not clear, however, what effect chemical modification of affinity Chromatographie techniques. The finca derivative DAVLB such "humanized" antibodies will have on their immunogenicity. The HYD was the generous gift of Mr. George Cullinan (Lilly Research present studies utilize a mouse antibody and rat host model to explore Laboratories, Indianapolis, IN). DAVLBHYD was conjugated to the aspects of this question. Rats injected with unmodified mouse monoclonal antibody as described utilizing a malonate linker (BAMME) (10) or a antibodies failed to mount anti-mouse immune responses, presumably BAP-based linker (11). due to their phylogenetic relatedness. In contrast, rats injected with a Rat Immunization Protocol Vinca immunoconjugate mounted strong anticonjugate antibody re sponses that were directed primarily against the linker portion of the conjugate. The in vivo serum pharmacokinetics of I2!l-labeled antibody Groups of young adult HaríanASI brown rats were injected i.p.
    [Show full text]
  • In Silico Prediction of Cancer Immunogens: Current State of the Art Irini A
    Doytchinova and Flower BMC Immunology (2018) 19:11 https://doi.org/10.1186/s12865-018-0248-x REVIEW Open Access In silico prediction of cancer immunogens: current state of the art Irini A. Doytchinova1 and Darren R. Flower2* Abstract Cancer kills 8 million annually worldwide. Although survival rates in prevalent cancers continue to increase, many cancers have no effective treatment, prompting the search for new and improved protocols. Immunotherapy is a new and exciting addition to the anti-cancer arsenal. The successful and accurate identification of aberrant host proteins acting as antigens for vaccination and immunotherapy is a key aspiration for both experimental and computational research. Here we describe key elements of in silico prediction, including databases of cancer antigens and bleeding-edge methodology for their prediction. We also highlight the role dendritic cell vaccines can play and how they can act as delivery mechanisms for epitope ensemble vaccines. Immunoinformatics can help streamline the discovery and utility of Cancer Immunogens. Keywords: Cancer immunogens, Databases of cancer immunogens, Prediction of cancer immunogens, Dendritic cell-based vaccines, Multi-epitope vaccines Background deaths in women; about 25% of all deaths. Yet over half Cancer is a catch-all term for a constellation of diseases of the global cancer burden occurs in less well developed typically characterised by abnormal cell division. The countries. Lung, bowel, liver, and stomach, are the com- term cancer can be traced to the Greek physician monest cancers globally, equating to 4 in 10 deaths Hippocrates (460-370 BC), who used the terms carcin- worldwide. At about 1 in 10 cases, smoking-related lung oma and carcinos to refer to ulcer-forming tumours and cancer is the commonest male cancer.
    [Show full text]
  • Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines
    cancers Review Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines 1, 1, 2,3, Bruno Bernardes de Jesus y , Bruno Miguel Neves y , Manuela Ferreira * and Sandrina Nóbrega-Pereira 1,4,* 1 Department of Medical Sciences and Institute of Biomedicine—iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] (B.B.d.J.); [email protected] (B.M.N.) 2 Center for Neuroscience and Cell Biology (CNC), University of Coimbra, UC Biotech, Biocant Park, 3060-197 Cantanhede, Portugal 3 Champalimaud Research, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal 4 Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.F.); [email protected] (S.N.-P.) These authors contributed equally to this work. y Received: 31 October 2020; Accepted: 27 November 2020; Published: 30 November 2020 Simple Summary: Effective cancer immunotherapies, with the objective to boost tumor-specific immune responses, is a game-changer in personalized cancer treatment. In immunotherapy, the immune system is exploited to recognize and destroy cancer cells, and this is only possible if a full recapitulation of tumor specific antigens complexity is achieved. Patient-derived induced pluripotent stem cells (iPSCs) share several characteristics with cancer (stem) cells (CSCs). The exploitation of iPSCs as a source of tumor- and patient-specific antigens guiding the immune system against cancer has been addressed recently in mice. Here, we will debate novel findings on the potential implication of cellular reprogramming and iPSCs plasticity for the design of novel cancer immunotherapeutic strategies.
    [Show full text]